Update on Urethral Bulking for Stress Urinary Incontinence in Women.
Bulking agents
Intrinsic sphincter deficiency
Periurethral injection
Stress incontinence
Journal
Current urology reports
ISSN: 1534-6285
Titre abrégé: Curr Urol Rep
Pays: United States
ID NLM: 100900943
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
24
05
2022
pubmed:
6
7
2022
medline:
19
10
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
Urethral bulking agents are an effective treatment for stress urinary incontinence in select females. The material and techniques used for urethral bulking are constantly evolving. With the introduction of several new agents, there is an ongoing debate over which agent is the most effective, durable, and safe. Current available bulking agents include Bulkamid®, Macroplastiue®, Durasphere®, Coaptite®, or Urolastic®. Each of these agents has its own biophysical properties that affect its efficacy and safety. Evidence evaluating bulking agents has increased over time but there is no definitive data that suggest superiority of one agent over another. The ideal urethral bulking agent for female stress incontinence has yet been identified. Currently available agents have acceptable short-term and medium-term efficacy with few adverse events.
Identifiants
pubmed: 35781870
doi: 10.1007/s11934-022-01099-5
pii: 10.1007/s11934-022-01099-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-209Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Dwyer L, Weaver E, Rajai A, Cox S, Reid F. “Voice your choice”: a study of women’s choice of surgery for primary stress urinary incontinence. Int Urogynecol J. 2020;31(4):769–77.
pubmed: 31853598
doi: 10.1007/s00192-019-04202-6
Zacche MM, Mukhopadhyay S, Giarenis I. Changing surgical trends for female stress urinary incontinence in England. Int Urogynecol J. 2019;30(2):203–9.
pubmed: 30523375
doi: 10.1007/s00192-018-3839-4
Kobashi K, Albo M, Dmochowski R, Ginsberg D, Goldman Ho, Gomelsky A, et al. American Urologic Association Stress-Urinary-Incontinence guideline. 2017;33.
Thüroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. EAU guidelines on urinary incontinence. Eur Urol. 2011;59(3):387–400.
pubmed: 21130559
doi: 10.1016/j.eururo.2010.11.021
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
pubmed: 12559262
doi: 10.1016/S0090-4295(02)02243-4
Winters JC, Dmochowski RR, Goldman HB, Herndon CDA, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72.
pubmed: 23098783
doi: 10.1016/j.juro.2012.09.081
Sirls LT, Richter HE, Litman HJ, Kenton K, Lemack GE, Lukacz ES, et al. HHS public access. 2015;189(1):204–9.
Bent AE, Foote J, Siegel S, Faerber G, Chao R, Gormley EA. Collagen implant for treating stress urinary incontinence in women with urethral hypermobility. J Urol. 2001;166(4):1354–7.
pubmed: 11547073
doi: 10.1016/S0022-5347(05)65768-0
Steele AC, Kohli N, Karram MM. Periurethral collagen injection for stress incontinence with and without urethral hypermobility. Obstet Gynecol. 2000;95(3):327–31.
pubmed: 10711537
Koski ME, Enemchukwu EA, Padmanabhan P, Kaufman MR, Scarpero HM, Dmochowski RR. Safety and efficacy of sling for persistent stress urinary incontinence after bulking injection. Urology. 2011;77(5):1076–80.
pubmed: 21216448
doi: 10.1016/j.urology.2010.10.010
Krhut J, Martan A, Jurakova M, Nemec D, Masata J, Zvara P. Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up. Int Urogynecol J. 2016;27(2):301–5.
pubmed: 26342812
doi: 10.1007/s00192-015-2834-2
Gomelsky A, Athanasiou S, Choo M-S, Cosson M, Dmochowski RR, Gomes CM, et al. Surgery for urinary incontinence in women: report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019;38(2):825–37.
pubmed: 30512219
doi: 10.1002/nau.23895
Appell RA, McGuire EJDP. Summary of effectiveness and safety in the prospective, open, multicenter investigation of Contigen implant for incontinence due to intrinsic sphincter deficiency in females. J Urol. 1994;151:418.
Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol. 2009;181(1):204–10.
pubmed: 19013613
doi: 10.1016/j.juro.2008.09.032
Stothers L, Goldenberg SL, Leone EF. Complications of periurethral collagen injection for stress urinary incontinence. J Urol. 1998;159(3):806–7.
pubmed: 9474154
doi: 10.1016/S0022-5347(01)63737-6
Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. J Urol. 2001;165(1):153–8.
pubmed: 11125386
doi: 10.1097/00005392-200101000-00037
Sweat SD, Lightner DJ. Complications of sterile abscess formation and pulmonary embolism following periurethral bulking agents. J Urol. 1999;161(1):93–6.
pubmed: 10037377
doi: 10.1016/S0022-5347(01)62074-3
Lightner D, Rovner E, Corcos J, Payne C, Brubaker L, Drutz H, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology. 2009;74(4):771–5.
pubmed: 19660800
doi: 10.1016/j.urology.2009.05.034
Hurtado E, McCrery R, Appell R. The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(8):869–73.
pubmed: 17103121
doi: 10.1007/s00192-006-0251-2
Berg S. Polytef augmentation urethroplasty: correction of surgically incurable urinary incontinence by injection technique. Arch Surg [Internet]. 1973;107(3):379–81. Available from: https://doi.org/10.1001/archsurg.1973.01350210017006 .
Malizia AAJ, Reiman HM, Myers RP, Sande JR, Barham SS, Benson RCJ, et al. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). JAMA. 1984;251(24):3277–81.
pubmed: 6374180
doi: 10.1001/jama.1984.03340480059030
Claes H, Stroobants D, Van Meerbeek J, Verbeken E, Knockaert D, Baert L. Pulmonary migration following periurethral polytetrafluoroethylene injection for urinary incontinence. J Urol. 1989;142(3):821–2.
pubmed: 2671416
doi: 10.1016/S0022-5347(17)38903-6
Christensen LH. Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers. Dermatologic Surg Off Publ Am Soc Dermatologic Surg [et al]. 2009;35(Suppl 2):1612–9.
doi: 10.1111/j.1524-4725.2009.01338.x
Ghoniem GM, Miller CJ. A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J. 2013;24(1):27–36.
pubmed: 22699885
doi: 10.1007/s00192-012-1825-9
Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183(4):1444–9.
pubmed: 20171691
doi: 10.1016/j.juro.2009.12.038
Hoe V, Haller B, Yao HH, O’Connell HE. Urethral bulking agents for the treatment of stress urinary incontinence in women: a systematic review. Neurourol Urodyn. 2021;40(6):1349–88.
pubmed: 34015151
doi: 10.1002/nau.24696
Serati M, Soligo M, Braga A, Cantaluppi S, Coluccia AC, Di Dedda MC, et al. Efficacy and safety of polydimethylsiloxane injection (Macroplastique(®)) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up. BJU Int. 2019;123(2):353–9.
pubmed: 30253026
doi: 10.1111/bju.14550
Tamanini JTN, D’Ancona CAL, Netto NR. Macroplastique implantation system for female stress urinary incontinence: long-term follow-up. J Endourol. 2006;20(12):1082–6.
pubmed: 17206907
doi: 10.1089/end.2006.20.1082
Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007;69(5):876–80.
pubmed: 17482925
doi: 10.1016/j.urology.2007.01.050
Palma PCR, Riccetto CLZ, Martins MHT, Herrmann V, de Fraga R, Billis A, et al. Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):670–1.
pubmed: 16341621
doi: 10.1007/s00192-005-0038-x
Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Snyder J, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology. 2001;58(1):12–5.
pubmed: 11445471
doi: 10.1016/S0090-4295(01)01148-7
Chrouser KL, Fick F, Goel A, Itano NB, Sweat SD, Lightner DJ. Carbon coated zirconium beads in beta-glucan gel and bovine glutaraldehyde cross-linked collagen injections for intrinsic sphincter deficiency: continence and satisfaction after extended followup. J Urol. 2004;171(3):1152–5.
pubmed: 14767290
doi: 10.1097/01.ju.0000103688.83606.06
Sokol ER, Aguilar VC, Sung VW, Myers DL. Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(5):643–7.
pubmed: 17965815
doi: 10.1007/s00192-007-0493-7
Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol. 2001;166(4):1350–3.
pubmed: 11547072
doi: 10.1016/S0022-5347(05)65767-9
Madjar S, Sharma AK, Waltzer WC, Frischer Z, Secrest CL. Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. J Urol. 2006;175(4):1408–10.
pubmed: 16516009
doi: 10.1016/S0022-5347(05)00679-8
Casteleijn FM, Kowalik CR, Berends C, Blaganje M, Lasić Pecev M, van der Linden E, et al. Patients’ satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: a cross-sectional study. Neurourol Urodyn. 2020;39(6):1753–63.
pubmed: 32526063
pmcid: 7497040
doi: 10.1002/nau.24417
De Vries AM, Van Breda HMK, Fernandes JG, Venema PL, Heesakkers JPFA. Para-urethral injections with Urolastic® for treatment of female stress urinary incontinence: subjective improvement and safety. Urol Int. 2017;99(1):91–7.
pubmed: 28152525
doi: 10.1159/000452450
Futyma K, Miotła P, Gałczyński K, Baranowski W, Doniec J, Wodzisławska A, et al. An open multicenter study of clinical efficacy and safety of urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. Biomed Res Int. 2015;2015: 851823.
pubmed: 26106616
pmcid: 4461699
doi: 10.1155/2015/851823
Lose G, Sørensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and mixed urinary incontinence. Int Urogynecol J. 2010;21(12):1471–7.
pubmed: 20645077
pmcid: 2977052
doi: 10.1007/s00192-010-1214-1
Christensen LH, Nielsen JB, Mouritsen L, Sørensen M, Lose G. Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig. Dermatologic surgery. 2008 Jun;34:S68–77.
Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J Urol. 2014;192(3):843–9.
pubmed: 24704117
doi: 10.1016/j.juro.2014.03.109
Itkonen Freitas A-M, Mentula M, Rahkola-Soisalo P, Tulokas S, Mikkola TS. Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: a randomized clinical trial. J Urol. 2020;203(2):372–8.
pubmed: 31479396
doi: 10.1097/JU.0000000000000517
Brosche T, Kuhn A, Lobodasch K, Sokol ER. Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. Neurourol Urodyn. 2021;40(1):502–8.
pubmed: 33410544
pmcid: 7839440
doi: 10.1002/nau.24589
Pai A, Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid(®)) in the management of stress and mixed urinary incontinence: three year follow up outcomes. Cent Eur J Urol. 2015;68(4):428–33.
Plotti F, Montera R, Terranova C, Luvero D, Marrocco F, Miranda A, et al. Long-term follow-up of bulking agents for stress urinary incontinence in older patients. Menopause. 2018;25(6):663–7.
pubmed: 29557846
doi: 10.1097/GME.0000000000001068
ter Meulen PH, Berghmans LCM, Nieman FHM, van Kerrebroeck PEVA. Effects of Macroplastique Implantation System for stress urinary incontinence and urethral hypermobility in women. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(2):177–83.
pubmed: 18936867
doi: 10.1007/s00192-008-0741-5
Corcos J, Collet JP, Shapiro S, Herschorn S, Radomski SB, Schick E, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology. 2005;65(5):898–904.
pubmed: 15882720
doi: 10.1016/j.urology.2004.11.054
Maher CF, O’Reilly BA, Dwyer PL, Carey MP, Cornish A, Schluter P. Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial. BJOG. 2005;112(6):797–801.
pubmed: 15924540
doi: 10.1111/j.1471-0528.2005.00547.x
Kirchin V, Page T, Keegan PE, Atiemo K, Cody JD, McClinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2012;(2):CD003881.
Jankowski RJ, Tu LM, Carlson C, Robert M, Carlson K, Quinlan D, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol. 2018;50(12):2153–65.
pubmed: 30324580
doi: 10.1007/s11255-018-2005-8
Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, Jach R, Uhl T, Basta A, et al. Autologous muscle-derived cells for the treatment of female stress urinary incontinence: a 2-year follow-up of a Polish investigation. Neurourol Urodyn. 2014;33(3):324–30.
pubmed: 23606303
doi: 10.1002/nau.22404